Jceler MV 1 Tablet SR is a combination oral antidiabetic medication containing Glimepiride (1mg), Metformin (500mg), and Voglibose (0.2mg), formulated to improve glycemic control in patients with type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, stimulates pancreatic beta cells to enhance insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, contributing to better glucose uptake and utilization. Voglibose, an alpha-glucosidase inhibitor, delays carbohydrate absorption in the intestines, leading to a reduction in postprandial hyperglycemia. The sustained-release formulation ensures a gradual and prolonged release of the active ingredients, promoting stable plasma concentrations and improved patient compliance. Jceler MV 1 Tablet SR is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes inadequately controlled by monotherapy or dual therapy. It is essential to monitor blood glucose levels regularly and adjust the dosage based on therapeutic response and tolerability. Caution is advised in patients with renal or hepatic impairment, and potential side effects include hypoglycemia, gastrointestinal disturbances, and lactic acidosis. This combination therapy offers a multifaceted approach to managing hyperglycemia by targeting different pathophysiological mechanisms of type 2 diabetes.

Dosage & How to Use